2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.25 Tupper

PP01.25 Tupper - Abstract

Pdf Summary

The document discusses the importance of biomarker testing in non-small cell lung cancer (NSCLC) and how the prevalence of targetable mutations may be more widespread than realized. The study evaluates the penetration of biomarker testing and the prevalence of targetable mutations in NSCLC patients, considering factors such as race, ethnicity, smoking status, cancer stage, and histologic subtype. The results show that 38.8% of patients underwent biomarker testing, with higher rates in Asian, non-smoking, advanced disease, and non-squamous histology groups. The most common mutations were observed in Asian patients, with EGFR mutations being prevalent in this group. However, EGFR mutations were also found in Hispanic patients, especially on exons 19 and 21. Less-tested mutations like MET and ERBB2 were more prevalent in Black patients, while BRAF and MET mutations were associated with a smoking history. The study emphasizes the need for early and equitable biomarker testing to improve targeted therapy outcomes and suggests stronger recommendations for broader testing in the population. The data underscores significant burdens of targetable mutations in overlooked groups and a high burden in expected groups, exceeding 50% in tested Asian patients. This study highlights the potential for biomarker-driven therapies to improve outcomes in NSCLC.

Keywords

biomarker testing

non-small cell lung cancer

NSCLC

targetable mutations

prevalence

race

ethnicity

smoking status

cancer stage

histologic subtype